BP 14979

Drug Profile

BP 14979

Alternative Names: BP 1.4979; BP1 4979

Latest Information Update: 16 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bioprojet
  • Class Smoking cessation therapies
  • Mechanism of Action Dopamine D3 receptor partial agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Restless legs syndrome; Smoking withdrawal

Most Recent Events

  • 06 Feb 2018 Phase-II clinical trials in Restless legs syndrome in France (PO) (NCT03345953)
  • 22 Nov 2017 Bioproject plans a phase II trial for Restless legs syndrome in France in January 2018 (NCT03345953)
  • 17 Mar 2016 Phase-II development is ongoing in France, Poland and Czech Republic
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top